Wed, November 30, 2011
Tue, November 29, 2011
Mon, November 28, 2011
Sun, November 27, 2011
Fri, November 25, 2011
Thu, November 24, 2011
Wed, November 23, 2011
Tue, November 22, 2011
Mon, November 21, 2011

Patient recruitment completed by Bausch + Lomb in glaucoma study


//science-technology.news-articles.net/content/2 .. -completed-by-bausch-lomb-in-glaucoma-study.html
Published in Science and Technology on Sunday, November 27th 2011 at 23:41 GMT by Market Wire   Print publication without navigation


November 28, 2011 01:38 ET

NICOX : Patient recruitment completed by Bausch + Lomb in glaucoma study

SOPHIA ANTIPOLIS, FRANCE--(Marketwire - Nov 28, 2011) -



PRESS RELEASE

NicOx: Patient recruitment completed by Bausch + Lomb in glaucoma study

[ www.nicox.com ]

NicOx S.A. (NYSE Euronext Paris: COX) today announced that the ongoing phase 2b study of BOL-303259-X, conducted by its partner Bausch + Lomb, has finished recruitment. Bausch + Lomb anticipates that the study will be completed by the end of December 2011, with preliminary results expected in the first quarter of 2012.

BOL-303259- is an NO-donating prostaglandin F2-alpha analog which is thought to lower intraocular pressure (IOP) through a dual mechanism of action. The ongoing study is intended to identify the most effective dose of BOL- 303259-X, administered in the evening to patients with open-angle glaucoma or ocular hypertension, for the reduction of IOP.

About NicOx

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a pharmaceutical company focused on the research, development and future commercialization of drug candidates. NicOx is applying its proprietary nitric oxide-donating R&D platform to develop an internal portfolio of New Molecular Entities (NMEs) for the potential treatment of inflammatory, cardio-metabolic and ophthalmological diseases.

The Company's pipeline includes several nitric oxide-donating NMEs, which are in development internally and with partners, who include Merck (known as MSD outside the United States and Canada), Bausch + Lomb, and Ferrer.

NicOx S.A. is headquartered in France and is listed on Euronext Paris (Compartment B: Mid Caps).

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.

Risks factors which are likely to have a material effect on NicOx's business are presented in the 4(th) chapter of the « Document de référence, rapport financier annuel et rapport de gestion 2010 » filed with the French Autorité des Marchés Financiers (AMF) on February 25, 2011 and available on NicOx's website ([ www.nicox.com ]) and on the AMF's website ([ www.amf-france.org ]).

NICOX: Patient recruitment completed by Bausch + Lomb in glaucoma study: [ http://hugin.info/143509/R/1566780/486563.pdf ]

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: NICOX via Thomson Reuters ONE

[HUG#1566780]



Publication Contributing Sources